業績

{ 139件 }

第65回日本リウマチ学会総会・学術集会 ICW Excellent Abstract Award 蜷川 慶太先生
  • 2021
  • 膠原病グループ
  • 受賞
Kato M, Michigami T, Tachikawa K, Kato M, Yabe I, Shimizu T, Asaka T, Kitagawa Y, Atsumi T. Novel mutation in the ALPL gene with a dominant negative effect in a Japanese family. Journal of Bone and Mineral Metabolism. in press IF: 2.297
  • 2021
  • 膠原病グループ
  • 欧文論文/原著
Miyoshi H, Baxter M, Kimura T, Hattori M, Morimoto Y, Marinkovich D, Tamiwa M, Hirose T. A real-world, observational study of the initiation, use, and effectiveness of basal-bolus or premixed insulin in Japanese people with type 2 diabetes. Diabetes Ther. 2021, in press IF: 3.179
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
Tsuchida K, Nakamura A, Miyoshi H, Yang K, Yamauchi Y, Kawata S, Omori K, Takahashi K, Kitao N, Nomoto H, Kameda H, Cho KY, Seino Y, Terauchi Y, Atsumi T. Glucokinase is required for high-starch diet-induced beta cell mass expansion in mice. J Diabetes Investig, in press. IF: 3.761
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
Shimatsu A, Nakamura A, Takahashi Y, Fujio S, Satoh F, Tahara S, Nishioka H, Takano K, Yamashita M, Arima H, Tominaga A, Tateishi S, Matsushita Y. Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: A multicenter, single-arm, phase 3 study in Japan. Endocr J, in press. IF: 1.952
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著

Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori Kazuno, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H.

Improved Time in Range and Postprandial Hyperglycemia with Canagliflozin in Combination with Teneligliptin: Secondary Analyses of the CALMER study.

Journal of Diabetes Investigation, in press

IF: 3.761 

  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
Nomoto H, Oba-Yamamoto C, Takahashi Y, Takeuchi J, Nagai S, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Kameda H, Cho KY, Nakamura A, Atsumi T, Miyoshi H. Effects of switching from liraglutide or dulaglutide to subcutaneous semaglutide on glucose metabolism and treatment satisfaction in patients with type 2 diabetes: protocol for a multi-center, prospective, randomized, open-label, blinded endpoint parallel-group comparison study (the SWITCH-SEMA 1 study). Diabetes Ther. 2020, in press IF: 3.179
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
Kimura Y, Higuchi I, Kobayashi M, Furugen A, Narumi K, Suzuki Y, Miyoshi H, Nakamura A, Atsumi T, Iseki K. The association between SLC16A11 haplotype and lipid metabolism in Japanese patients with type 2 diabetes. Drug Metab Pharmacokinet, in press. IF: 2.772
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
Miya A, Nakamura A, Cho KY, Nomoto H, Kawata S, Sugawara H, Takeuchi J, Nagai S, Tsuchida K, Omori K, Yokoyama H, Taneda S, Kurihara S, Aoki S, Atsumi T, Miyoshi H. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin Journal of Diabetes Investigation, in press IF: 3.761 
  • 2021
  • 糖尿病・内分泌グループ
  • 欧文論文/原著
  • 2020
  • 腎臓グループ